If you need help accessing our website, call 855-698-9991
Skip to main content
NYU Langone Provider

Peter M. Izmirly, MD

NYU Langone Provider
  • Specialty: Rheumatology
  • Treats: Adults
  • Language: English

Positions
Board Certifications
  • American Board of Internal Medicine (Rheumatology), 2006
Education and Training
  • Fellowship, New York University School of Medicine, Rheumatology, 2007
  • Residency, New York University-Bellevue Hosptial Center, Internal Medicine, 2004
  • MD from New York University, 2001

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

View All Accepted Plans This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

Peter M. Izmirly, MD does not accept insurance.

Interests

lupus , epidemiology , neonatal lupus , lupus nephritis

Academic Contact

Academic office

550 First Avenue

6th Floor, MSB 625

New York, NY 10016

Phone

212-263-5802

Fax

646-501-5208

These focus areas and their associated publications are derived from PubMed and the MeSH term library. *
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

  • Pilot Study: Feasibility acceptability and adaptation. We will produce a teaching video for home-based proteinuria testing that will instruct patients on how to collect a sample and evaluate the home colorimetric dipsticks (only protein Siemens Albutri

    Learn More
  • In this research proposal we will develop a clinical registry containing information related to the patient s ethnicity race gender age medications specific disease or state of health and biorepository (tissue bank collection of blood samples ur

    Learn More
  • Cutaneous lupus erythematosus (CLE) includes three main subsets: acute CLE (ACLE) subacute CLE (SCLE) and chronic CLE (CCLE) the latter including discoid lupus erythematosus (DLE). Lesion progression may lead to significant scarring and dyspigmentation

    Learn More
View All Research Studies (5)

Read All Publications (227)

Related News